Fatal interstitial lung disease associated with oral erlotinib therapy for lung cancer

被引：0
作者：
Demosthenes Makris
Arnaud Scherpereel
Marie Christine Copin
Guillaume Colin
Luc Brun
Jean Jacques Lafitte
Charles Hugo Marquette
机构：
[1] CHRU of Lille,Pulmonary and Thoracic Oncology Department
[2] INSERM Unit 774,Pathology Department
[3] Institut Pasteur of Lille,Clinique des Maladies Respiratoires
[4] CHRU of Lille,undefined
[5] Hôpital Albert Calmette,undefined
[6] CHRU de Lille,undefined
来源：
BMC Cancer | / 7卷
关键词：
Docetaxel; Gemcitabine; Human Epidermal Growth Factor Receptor; Erlotinib; Interstitial Lung Disease;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Fatal acute interstitial lung disease associated with docetaxel administration: about a case and review of the literature
    Aziz Brahmi, Sami
    Youssef, Seddik
    Zahra Ziani, Fatima
    Afqir, Said
    PAN AFRICAN MEDICAL JOURNAL, 2016, 24
  • [22] High exposure to erlotinib and severe drug-induced interstitial lung disease in patients with non-small-cell lung cancer
    Fujita, Ken-ichi
    Hirose, Takashi
    Kusumoto, Sojiro
    Sugiyama, Tomohide
    Shirai, Takao
    Nakashima, Masanao
    Akiyama, Yuko
    Sasaki, Yasutsuna
    LUNG CANCER, 2014, 86 (01) : 113 - 114
  • [23] Cancer and interstitial lung disease
    Artinian, V
    Kvale, PA
    CURRENT OPINION IN PULMONARY MEDICINE, 2004, 10 (05) : 425 - 434
  • [24] Rituximab therapy in interstitial lung disease associated with rheumatoid arthritis
    Fui, Annalisa
    Bergantini, Laura
    Selvi, Enrico
    Mazzei, Maria A.
    Bennett, David
    Pieroni, Maria G.
    Rottoli, Paola
    Bargagli, Elena
    INTERNAL MEDICINE JOURNAL, 2020, 50 (03) : 330 - 336
  • [25] Interstitial Lung Disease Associated with Docetaxel in Patients with Advanced Non-small Cell Lung Cancer
    Tamiya, Akihiro
    Naito, Tateaki
    Miura, Satoru
    Morii, Sakae
    Tsuya, Asuka
    Nakamura, Yukiko
    Kaira, Kyoichi
    Murakami, Haruyasu
    Takahashi, Toshiaki
    Yamamoto, Nobuyuki
    Endo, Masahiro
    ANTICANCER RESEARCH, 2012, 32 (03) : 1103 - 1106
  • [26] Successful erlotinib rechallenge for leptomeningeal metastases of lung adenocarcinoma after erlotinib-induced interstitial lung disease: A case report and review of the literature
    Togashi, Yosuke
    Masago, Katsuhiro
    Hamatani, Yasuhiro
    Sakamori, Yuichi
    Nagai, Hiroki
    Kim, Young Hak
    Mishima, Michiaki
    LUNG CANCER, 2012, 77 (02) : 464 - 468
  • [27] Interstitial lung disease associated with gemcitabine treatment in patients with non-small-cell lung cancer and pancreatic cancer
    Shigeki Umemura
    Hiromichi Yamane
    Toshimitsu Suwaki
    Tsutomu Katoh
    Takuya Yano
    Yasuhiro Shiote
    Nagio Takigawa
    Katsuyuki Kiura
    Haruhito Kamei
    Journal of Cancer Research and Clinical Oncology, 2011, 137 : 1469 - 1475
  • [28] Nationwide survey of radiation therapy in Japan for lung cancer complicated with interstitial lung disease
    Hagiwara, Yasuhito
    Nakayama, Yuko
    Kudo, Shigehiro
    Hayakawa, Toyokazu
    Nakamura, Naoki
    Kitamoto, Yoshizumi
    Takahashi, Shigeo
    Tsujino, Kayoko
    Kubo, Nobuteru
    Tamaki, Yukihisa
    Nagata, Yasushi
    JOURNAL OF RADIATION RESEARCH, 2020, 61 (04) : 563 - 574
  • [29] Erlotinib/ciprofloxacinFatal interstitial lung disease in an elderly patient with elevated erlotinib levels due to a ciprofloxacin/erlotinib interaction: case report
    Reactions Weekly, 2012, 1397 (1) : 16 - 16
  • [30] Does interstitial lung disease predispose to lung cancer?
    Daniels, CE
    Jett, JR
    CURRENT OPINION IN PULMONARY MEDICINE, 2005, 11 (05) : 431 - 437
12345